Pet testing growth powers through softer clinic visits
- IDEXX is mainly a companion animal diagnostics company, with CAG making up most of its revenue.
- The core engine is recurring testing revenue from consumables, reference labs, and software used by vet clinics.
- Q2 2026 was strong, with CAG Diagnostics recurring revenue growing 10.3% organically.
- The company placed 1,600 inVue Dx analyzers in Q2, keeping it on track for the 5,500 full-year goal.
- Weaker U.S. clinic traffic remains a headwind, declining 1.3% in the second quarter.
Strong tests, softer visits
IDEXX has a strong setup because vet clinics keep using its tests once its machines and software are inside the practice. That makes a large part of sales repeatable. In Q2 2026, overall organic revenue grew 9%, led by a 10.3% organic gain in CAG Diagnostics recurring revenue.
The inVue Dx launch remains a major growth driver. IDEXX placed 1,600 inVue Dx analyzers in Q2 and is tracking well toward its 5,500 full-year target. New catalysts are approaching, including a Cancer Dx panel expansion in late Q3 and the broader launch of fine needle aspirate capabilities by year-end.
The bear case centers on macroeconomic pressure. U.S. clinic visits declined 1.3% in Q2. While IDEXX outperformed this drop through higher prices and test utilization, prolonged weakness in vet visits could eventually limit top-line growth if owners delay non-essential care.
Machines seed repeat tests
IDEXX works like a razor and blades business. The company places diagnostic machines in vet clinics. Then it sells the single-use tests, service, lab work, and software that clinics use again and again.
This model can be sticky. A clinic that uses IDEXX instruments, reference labs, and practice software has to change workflows to switch. That helps retention and gives IDEXX room to raise prices when the value is clear.
The model can break if clinics run fewer tests per visit, delay new instrument purchases, or shift to a cheaper rival. It can also slow if a new platform like inVue Dx gets placed, but consumable use per machine takes longer than expected to build.
Tests at the clinic and the lab
Point-of-care veterinary diagnostics
This includes Catalyst, ProCyte, inVue Dx, rapid assays, and related consumables. The instruments seed future test use inside the clinic.
VetLab consumables
These are the single-use test materials used on IDEXX machines. They provide a highly profitable, recurring revenue stream.
Reference laboratory services
IDEXX runs labs that handle tests a clinic does not run in-house. The upcoming Cancer Dx panel expansion adds mast cell tumor detection.
Veterinary software and imaging
Products like ezyVet and Neo help clinics run records, billing, and workflows. Software also helps tie the clinic more closely to the IDEXX system.
Water testing
This business sells products that test water for microbes. Q2 2026 Water revenue grew 13% organically.
Livestock, Poultry and Dairy diagnostics
This segment sells tests used for herd, flock, and milk safety. Q2 2026 LPD revenue grew 9% organically.
OPTI Medical and other
This is a small human medical diagnostics and out-licensing bucket. It is too small to drive the main thesis.
Mostly companion animal care
Segment mix is based on Q1 2026 revenue. The Companion Animal Group remains the dominant driver, making this mostly a bet on pet diagnostics and vet clinic demand.
What could go wrong
Clinic visits keep falling
High impact · Medium oddsIDEXX can grow even when visits slip, but there is a limit. U.S. clinic visits fell 1.3% in Q2 2026. A deeper drop would pressure test volumes and make the raised guidance harder to hit.
Consumable pull-through disappoints
Medium impact · Medium oddsPlacing machines is only the first step. The better business comes when clinics use the machines often and buy more consumables. The FNA use case for inVue Dx expands later in 2026, but the speed of revenue lift is an open question.
Instrument growth faces tough comparisons
Medium impact · High oddsInstrument revenue surged earlier in the year, helped by inVue Dx. That creates a high hurdle for the rest of the year as the company laps the early launch surge.
Global costs and currency move against it
Medium impact · Medium oddsIDEXX sells around the world and buys through global supply chains. Currency moves, tariffs, shipping delays, or higher input costs can hurt reported growth or margins.
In one breath
How does IDEXX make most of its money?
Most revenue comes from the Companion Animal Group. The key stream is recurring diagnostics revenue, such as VetLab consumables, reference lab services, and related clinic services.
Why is inVue Dx important for IDEXX?
inVue Dx is a newer point-of-care analyzer for cytology and blood cell testing. Each placement can add future consumable sales, which is why the 5,500 placement target for 2026 matters.
What is the biggest risk for IDXX stock?
The biggest business risk is that pet owners pull back on vet visits and testing. The stock also needs IDEXX to keep proving that growth can stay strong while clinic visits are still down.
